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ABSTRACT 
Microvesicles (MV) were once thought to be inert cellular fragments; however, a large body 
of research suggests they are bioactive components involved in intercellular communication and 
altering physiological processes. As these 100 nm – 1 µm plasma membrane-derived vesicles are 
formed from many cell types, they vary significantly in composition and function. Recently, it has 
been shown that high intensity exercise increases the concentration of circulating platelet-derived 
MVs. While the physiological role of these MVs is unknown, they have been shown to improve 
the functionality of endothelial cells, indicating a potential for mediating the adaptive effects of 
exercise on the cardiovascular system. The present study aims to further examine the effects of 
these exercise-derived MVs on the endothelium, as well as investigate the mechanism by which 
MVs and endothelial cells interact. Exercise trials were performed to produce blood MV samples 
from eleven participants. To test the effects of exercise-derived MVs, cultured endothelial cells 
were treated with MV samples from rest, exercise or recovery. Endothelial cell function, in terms 
of proliferation and wound-healing, was examined. To gain insight into the mechanism of 
interaction between exercise-derived MVs and endothelial cells, blockade studies were 
incorporated into the functional assays. MV surface proteins were degraded with trypsin and the 
interaction between Axl and Gas6 was inhibited with an anti-Axl antibody. Several mistakes were 
made within the course of this study, including incorrect preparation of the sodium citrate 
anticoagulant used for blood sample collection and possible microbial contamination of 
endothelial cell cultures. As such, the results of this study are inconclusive and further research is 
required to determine the effect of exercise-derived MVs on endothelial cell function and the 
pathways involved in this interaction. 
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1 LITERATURE REVIEW 
1.1 The discovery of microvesicles 
In Darwin’s book, “The Variation of Plants and Animals under Domestication” (1868), he 
proposed that cells “throw off minute granules” that circulate throughout the body.1 Darwin named 
these cellular granules “gemmules” and thought that they were involved in the incorrectly 
hypothesized inheritance of acquired characteristics. Of course, Darwin was mistaken about the 
function of these gemmules, but he had nonetheless foreshadowed the discovery of microvesicles 
(MVs). In 1967, while investigating the mechanisms of blood coagulation, Peter Wolf described 
what he called “platelet dust”.2 This platelet dust, isolated by high-speed centrifugation, showed 
procoagulant activity, and was thought to explain the mystery of platelet-free plasma coagulation. 
Wolf’s “dust” was soon after termed microparticles, and later renamed microvesicles to avoid 
confusion with non-cellular microparticles. 
In the fifty years since Wolf published his article describing platelet dust, a large body of 
research has expanded the understanding of these cellular packages. In 1970, Webber and Johnson 
took the first images of the formation and release of MVs from platelets.3 They found that thrombin 
initiates the formation of what they described as concentric rings and hollow spheres within the 
platelet cytoplasm, which are released from the cell. Four years after Wolf’s discovery, Crawford 
used electron microscopy to image platelet MVs (PMV), describing them as having a 
heterogeneous granular appearance, ranging between 20 to 40 nm in diameter.4 Further, electron 
micrographs of platelets showed blebbing of the plasma membrane that was structurally similar to 
the granule-like PMVs. This observation, with the findings that the MV homogenates showed 
ATPase activity and contained actomyosin-like contractile proteins similar to those of platelets, 
led Crawford to hypothesize that PMVs originated from this membrane blebbing. 
In 1987, Johnstone et al. described a new population of cellular vesicles while investigating 
erythrocyte production. They found that these small vesicles, termed exosomes, were released 
from reticulocytes (immature erythrocytes) and contained enzymes and transmembrane 
transporters characteristic of reticulocytes.5  Since then, exosomes have been shown to be just as 
diverse in form and function as MVs.6 In fact, platelets, among other cell types, have been shown 
to produce both MVs and exosomes.7 These two populations are differentiated based on size and 
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mechanism of formation; MVs are defined as 100 nm to one µm plasma-membrane derived 
vesicles, while exosomes are less than 100 nm in diameter and are formed intracellularly (Figure 
1). 
 
Figure 1. Cryo-electron micrographs of extracellular vesicles isolated by protein organic solvent precipitation with MVs (>100 nm) 
and exosomes (<100 nm) present. Scale bars = 55 nm. (Figure from Gallart-Palau et al. (2015)8 ). 
An article published in 1977 suggested that membranous particles, isolated by 
ultracentrifugation or gel filtration of urine and cell culture media, contain both membrane-bound 
and cytoplasmic enzymes.9 This finding illuminated the fact that these extracellular vesicles (EV) 
carry membrane and cytoplasmic contents of their parental cell. Indeed, EVs are bioactive 
components involved in intercellular communication and altering physiological processes and are 
often associated with disease states. MVs carry a variety of cytokines and signalling molecules 
that modify the phenotype and function of cells that they interact with through fusion, endocytosis 
or induction of signalling cascades. MVs also deliver mRNA and microRNA to target cells, where 
de novo translation or translational regulation induces changes in protein expression and cellular 
behavior.10,11 MVs are derived from every cell type, including tumor cells, and are found in all 
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biological fluids, including breast milk,12 cerebrospinal fluid,13 semen,14 urine,15 and blood. The 
cargo carried by MVs is taken from the parental cell and transported throughout the body through 
the circulatory system, allowing stationary cell types to have far reaching effects. However, the 
cargo composition can be significantly different from the contents of the parental cell, depending 
on the agonist that induced MV formation, complicating the relationship between MV type and 
function.11  
1.2 Microvesiculation 
MVs are formed from many cells types, including leukocytes, erythrocytes, endothelial cells, 
and platelets (PMV), with PMVs making up the majority of the circulating MV population. MV 
formation is induced by cellular activation or apoptosis. In terms of PMVs, this activation may 
come in the form of collagen, Ca2+, thrombin, norepinephrine, or shear stress.16 In vitro production 
of PMVs is often conducted using thrombin, or thrombin receptor-activating protein (TRAP).10,17 
The processes behind the formation of MVs have been best characterized in terms of PMVs but 
the complete mechanism of how many agonists induce formation is unknown. 
Activation begins with stimulus from an agonist, such as thrombin, binding to platelet 
surface receptors (Figure 2). The stimulus activates phospholipase C-β (PLC), which hydrolyses 
phosphatidylinositol 4,5-biphosphate (PIP2) in the inner leaflet of the plasma membrane to yield 
membrane-bound diacylglycerol (DAG) and cytoplasmic inositol 1,4,5-triphosphate (IP3). IP3 
triggers the release of Ca2+ from internal stores, in turn inducing the influx of extracellular Ca2+.18 
This cascade results in a dramatic increase in cytosolic Ca2+ concentration, which causes 
cytoskeletal remodelling by a conformational change in cytosolic calpain, forming an active 
protease that cleaves cytoskeletal proteins.19,20 Experiments that have artificially induced PMV 
formation through the application of a Ca2+ ionophore and TRAP, evoke Cdc42 and Rac1 G 
proteins, which mediate actin modification and cytoskeletal reorganization through the p21-
activated kinase (PAK).21 However, inhibiting upstream at calpain does not completely blunt PMV 
production, suggesting other mechanisms are involved.21 Indeed, other agonists likely invoke 
different pathways. Regardless of the pathway involved, cytoskeletal degradation results in 
detachment of areas of the plasma membrane, which protrude from the cell and eventually bleb 
off to form MVs. 
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Figure 2. Pathway of platelet activation leading to microvesicle formation. Biogenesis begins by cellular activation (1), which 
initiates a PIP2 signalling cascade (2) that results in an increase in the cytoplasmic Ca2+ concentration (3). Calpain is activated and 
degrades the actin cytoskeleton, disrupting the plasma membrane (4), inducing the formation of blebs that separate from the cell 
(5). 
Phosphatidylserine (PS), an anionic phospholipid, is usually present on the inner leaflet of 
the plasma membrane; however, during platelet activation and MV formation, PS becomes 
externalized.22 Ca2+ inhibits the transmembrane lipid transporter flippase, which is responsible for 
maintaining membrane asymmetry by inward PS translocation. The increase of cytosolic Ca2+ also 
activates scramblases, which allow for random movement of phospholipids between the inner and 
outer membrane leaflets.22,23 Together, these two mechanisms result in PS expression on the outer 
membrane leaflet of MVs. While some studies have suggested that PS exposure is not 
characteristic of all MV populations, PS is assumed to be expressed on the surface of PMVs.24 
5 
 
1.3 Isolation and quantification of MV populations 
As there are several methods used to isolate MVs rather than one standard procedure, reported 
MV concentrations and population characteristics are highly variable between studies. 
Centrifugation is a simple method of isolation, usually using two centrifugation steps to remove 
first the blood cells, and then platelets, with a third high-speed centrifugation to pellet MVs. While 
centrifugation is the most widely used isolation method throughout literature, there is no consistent 
centrifugation speed and time, leading to potentially inconsistent results between different labs. 
An attempt was made by the Society of Thrombosis and Haemostasis to standardize the process 
of blood collection and MV isolation.25 This report highlights the importance of not just consistent 
isolation methods, but handling of samples, as factors such as the blood draw procedure, the choice 
of anticoagulant, freezing, and the time before processing can affect the MVs in the sample.25 
However, many studies published after the release of this report do not comply with the 
standardized procedure. Centrifugation can be paired with density gradients and filters to improve 
sample purity, but these methods may reduce the MV yield, making the results difficult to compare 
to similar studies.26  
A novel method of protein organic solvent precipitation (PROSPR) enables effective 
purification of intact MVs and exosomes in plasma by removing soluble proteins with acetone.8 
While this method is ideal for analysis of cargo proteins, nucleic acids and lipids, it is not 
appropriate for functional assays because the acetone precipitation may denature functional surface 
markers used to identify MV populations. Another method that is useful for characterization, but 
not for functional studies, is the use of magnetic beads conjugated to MVs with specific binding 
proteins, such as annexin V, lactadherin or MV antigen specific antibodies.27 Because MVs carry 
surface markers from their parental cell, they can be characterized in terms of their origin. PMVs 
typically carry CD41 (integrin α2β), leukocyte MVs can be identified by exposed CD45 (protein 
tyrosine phosphatase, receptor type C), and endothelial MVs carry both CD144 (vascular cell 
adhesion protein 1) and CD62E (E-selectin).28 The bead-bound MVs can be easily isolated with a 
magnet. However, the addition of the magnetic beads is non-reversible and could potentially 
interfere with interactions between cells and MVs. This method further suffers from poor yield 
and nonspecific binding. 
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These methods have the disadvantage of not differentiating between MVs and exosomes. 
Even with size-gating, MV and exosome populations cannot be completely separated due to 
overlap in size. As such, it is nearly impossible to investigate the characteristics and functions of 
just MVs or exosomes, and rather EVs are better characterized by surface markers. Also, because 
MV and exosome populations overlap in size, methods that count MVs based on size may over 
estimate MV concentrations. 
As with isolation, there is no standard methodology for MV enumeration and these methods 
do not reliably differentiate between MVs and exosomes, resulting in inconsistent estimates of 
MV concentration. Flow cytometry is the most commonly used method of enumerating MVs. 
However, this approach has a drawback in that small MVs and exosomes are not reliably detected 
by previous generation flow cytometers.29 To detect the smaller MVs, they can be conjugated to 
beads that increase light scattering, but, as described above, this method prevents the MVs from 
being used in subsequent functional studies. However, new generation flow cytometers enable 
detection of MVs smaller than 200 nm, which has increased accurate MV quantification.30 In fact, 
when using flow cytometers that can detect vesicles in this range, the calculated MV concentration 
increases dramatically.31 Nanoparticle tracking analysis, in which a laser monitors the Brownian 
motion of small particles, is also used for MV quantification and can measure the size of individual 
MVs.32 This method is effective at detecting MVs 70 nm and larger, and, with the incorporation 
of antigen-specific fluorescent labelling, MV subsets within a sample can be differentiated.32  
1.4 Mechanisms of interaction 
MVs interact with target cells through many pathways. MVs may induce signalling cascades 
by binding receptor proteins on the surface of target cells, or may fuse to, or be taken up by, the 
target cell.33 MVs may also lyse, releasing cargo into the blood, allowing the contents to interact 
with cell surface receptors. Regarding PMV interactions with endothelial cells, the majority of 
research indicates MVs are taken up via receptor-mediated endocytosis. The mechanisms that 
induce endocytosis of MVs are unclear and many pathways have been proposed. Membrane lipids, 
specifically PS, and endothelial surface receptors have been implicated in several pathways.34,35 
Baj-Krzyworzeka et al. (2002) found that degradation of  PMV surface proteins with trypsin or 
proteinase K increases MV uptake by endothelial cells, indicating that PS is mediating the 
interaction and removal of surface proteins allows for easier access of PS to receptors.36 However, 
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Faille et al. (2012) found that trypsin degradation decreased PMV endocytosis by endothelial cells, 
suggesting that MV surface proteins are involved in uptake.34 These results highlight an important 
aspect of MVs; the characteristics of MVs are dependent on the stimulus of production as well as 
the cell of origin. While Baj-Krzyworzeka et al. (2002) activated platelets with thrombin and 
collagen, Faille et al. (2012) used a calcium ionophore. 
 Developmental endothelial locus-1 (Del-1), a glycoprotein secreted by endothelial cells, has 
been shown to be involved in PMV clearance from the circulatory system by bridging MVs and 
endothelial cells.37 Del-1 contains binding domains for both integrin αvβ3, which is expressed on 
the endothelial plasma membrane, and PS, thus allowing endothelial cells to bind PS-expressing 
MVs.38,39 Antibody inhibition of Del-1, annexin V blockade of PS and pharmacological inhibition 
of clathrin with chlorpromazine all decrease the uptake of platelet MVs by endothelial cells, 
implicating Del-1 in clathrin-dependent endocytosis of PMVs.37  Similarly, lactadherin, an opsonin 
secreted by endothelial cells into the blood, mediates PMV internalization by endothelial cells by 
binding MV phosphatidylserine and endothelial integrin αvβ3.17 Interestingly, MVs from 
apoptotic endothelial cells have been shown to express annexin V, which mediates uptake by 
binding PS on the outer leaflet of apoptotic endothelial cells.35  
Of particular interest to the current study is the 
TAM (Tyro3, Axl and Mer) receptor, Axl, and its 
ligand, Gas6. A recent report indicated that Gas6 
bridges PMVs and endothelial cells by binding both 
Axl, expressed on the surface of endothelial cells, 
and PS on PMVs (Figure 3).40 Gas6 is produced by 
endothelial cells and is found in plasma at a 
concentration of 13 to 23 ng/mL.41,42 TAM 
receptors are important for clearance of apoptotic 
cells by macrophages and dendritic cells, and 
because MVs share characteristics with apoptotic 
cell fragments, such as externalized PS, this 
pathway may be involved in the clearance of MVs 
by endothelial cells.43 This Axl/Gas6 interaction 
Figure 3. The mechanism of endothelial cell and MV 
binding via Axl/Gas6. Image from Federation of 
American Societies for Experimental Biology 
(http://www.fasebj.org/content/30/1_Supplement/1117
.1/F1.expansion.html) 
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results in PMV internalization by human umbilical vein endothelial cells (HUVECs) and the 
addition of anti-Axl antibody inhibits this uptake.40 
While multiple PMV internalization mechanisms by endothelial cells have been reported, the 
mechanism has not been investigated in models involving exercise-derived MVs. However, it is 
probable that mechanisms are not exclusive to exercise-derived MVs, as agonists typical of an 
exercise state, such as thrombin, collagen, and shear stress, are upregulated during coagulation 
cascades and other physiological responses. 
1.5 Effects of microvesicles on endothelial cells 
The effect of MVs on the endothelium, the lining of endothelial cells that covers blood vessel 
walls, has not been extensively investigated. However, there have been several papers that suggest 
deleterious effects from MV populations associated with disease states. MVs from apoptotic T 
cells and from patients with metabolic disease increase in vitro endothelial dysfunction by inducing 
endoplasmic reticulum stress and activating the unfolded protein response, which increases 
cytoplasmic reactive oxygen species and decreases nitric oxide synthase activity.44 This response 
increases cellular stress and reduces the ability of endothelial cells to induce vasodilation.45  
Disease states, such as late-stage pulmonary arterial hypertension (PAH), increase circulating MV 
concentrations, and these MVs stimulate intracellular adhesion molecule-1 (ICAM-1) expression 
by cultured pulmonary arterial endothelial cells.46 This may be an adaptive response, as ICAM-1 
aids immune cells in infiltrating lung tissues, but the increase in inflammatory cytokines released 
by leukocytes can cause deleterious complications.46 A high-fat diet leading to obesity in rats 
increases circulating concentrations of endothelial, platelet, monocyte and T-cell MVs.47 These 
MVs upregulate the expression of vascular cell adhesion molecule-1 and reactive oxygen species 
in cultured endothelial cells, similar to that seen in late-stage PAH.47 Further effects of monocyte-
derived MVs include in vitro induction of endothelial cell apoptosis by delivering active caspase-
1, a protease that has been shown to induce apoptosis through the NF-κB signalling pathway that 
is involved in transcriptional regulation of genes such as TNFα (tumor necrosis factor), TNFβ and 
β-Interferon, indicating that MVs may be involved in regulation endothelial cell survival.48,49 
While MVs can have deleterious effects on the endothelium, they can also have adaptive 
effects. MVs can induce angiogenesis, which involves proliferation and migration of endothelial 
cells. CD40 ligand positive MVs isolated from atherosclerotic lesions induce neovascularization 
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of plaques by binding CD40 on endothelial cells in vitro, which results in expression of several 
angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth 
factor.50 Although formation of the vasa vasorum in atherosclerotic plaques is detrimental and may 
cause lesion rupture, this mechanism may be active in other regions of the cardiovascular system 
where angiogenesis is beneficial, such as in muscle tissue. PMVs improve the ability of circulating 
angiogenic cells (CAC), isolated from atherosclerotic patients, to adhere to the endothelium, after 
which they migrate into the intercellular spaces between endothelial cells and release pro-
angiogenic cytokines.51 PMV-treated CACs also increase neovascularization when administered 
to rats with hind limb ischemia, improving oxygenation of ischemic tissues. This effect has also 
been seen with rats treated with PMVs from healthy donors, suggesting that PMVs may be 
interacting with CACs in vivo, or are inducing neovascularization of ischemic tissue through a 
separate mechanism.51,52 PMVs may induce angiogenesis through activation of phosphoinositide 
3-kinase by releasing VEGF that binds to surface receptors, initiating a signaling cascade that 
results in endothelial proliferation, migration and angiogenesis, both in in vitro and in vivo 
models.52 However, endothelial MVs have the opposite effect, reducing the length of new 
capillaries and decreasing the number of branch points in capillary networks in vitro.53 A recent 
study linked exercise-derived MVs, consisting primarily of PMVs, to increased proliferation, 
angiogenesis and wound healing of cultured endothelial cells and it is possible that this is due to 
an increase in platelet derived MVs.54 
1.6 Microvesicles and exercise 
High intensity exercise has been shown to increase circulating MV concentrations, but the 
findings are somewhat inconsistent between studies. Chaar et al. (2011) found that strenuous 
exercise increased total circulating MV concentrations from 1000 MVs/µL to 4000 MVs/ µL and 
this increase persisted for two hours after cessation of exercise.55 Further, this increase was 
attributed mainly to PMVs, while erythrocyte, monocyte, and endothelial MV populations did not 
increase. Studies from Sossdorf et al. (2010) and Maruyama et al. (2012) have identified similar 
trends in MV dynamics, although the magnitude of exercise-derived PMV increase varied from a 
nearly three-fold increase to a moderate increase of less than 25%, respectively.56,57 Another study 
focused on exercise-derived EVs between 100 and 300 nm, which includes exosomes as well as 
small MVs.58 Similar to larger MVs, the concentration of these small EVs increased 2.7-fold, 
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although the increase was not maintained at 90 minutes post-exercise. On the other hand, Mobius-
Winkler et al. (2009) identified no significant increase in total circulating MV concentrations or in 
the specific endothelial MV population after exercise.59 The experimental design included exercise 
at 70% of anaerobic threshold, while studies that found significant increases in MV concentrations 
used 80 to 85% of maximal aerobic power or, in the case of Chaar et al. (2011), repeated maximal 
exercise designed to simulate training sessions. It is possible that high enough exercise intensity 
was not achieved in the Mobius-Winkler et al. (2009) study, but a minimal exercise intensity 
necessary to induce MV production has not been determined. 
Although the mechanism behind the exercise-derived MV increase is not completely 
understood, explanations include a reduction in plasma volume, an increase in platelets and 
leukocytes as well as an increase in MV agonists.56 Exercise causes plasma to migrate into the 
extravascular tissue and contracting muscle, reducing plasma volume and increasing the relative 
concentration of blood constituents,60 including red blood cells, leukocytes and platelets.61,62 As 
exercise intensity increases, blood concentrations of many known platelet agonists, such as 
norepinephrine and ADP, increase substantially. As well, increased heart rate and blood pressure 
increase shear stress and these combined factors may be responsible for the increase in circulating 
MVs. This is further supported by the increase in PS-expressing MVs, which are generally 
assumed to be of platelet origin.56  
1.7 Therapeutic potential 
While much research has indicated harmful effects of MVs, a new focus has been on using 
MVs for the treatment of various diseases, such as cancer. MVs are ideal for therapeutic 
applications; MV membranes are stable and resistant to lysis, in vitro preparation is relatively 
simple, and they benefit from being endogenous and thus have a low risk of inciting an immune 
response. A recent article showed that tumor-derived MVs, when taken up by bladder tumor cells, 
increase sensitivity to chemotherapy by reducing efflux of the drugs and inducing entry of the 
drugs into the nucleus.63 While this treatment prevented tumor growth in rats and increased 
survival rate, it carries risk, as tumor-derived MVs are also involved in the modulation of the tumor 
microenvironment and supporting tumor growth.64  
MVs have also been investigated for application as a drug delivery system. Through 
electroporation, MVs were loaded with siRNAs and chemotherapy medication and were injected 
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into mice with breast cancer, effectively reducing tumor size.65 This study highlights the versatile 
applications of MVs for drug delivery, as MVs were engineered with surface markers to target 
them to specific cells. Although these studies are promising, MVs are still poorly understood and 
further characterization of cargo and pathophysiology are required before therapeutic applications 
are possible in humans. 
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2 INTRODUCTION 
Exercise is important for maintaining proper health and preventing cardiovascular disease 
(CVD) by significantly reducing associated risk factors. High dose lipid lowering drugs and blood 
pressure medications are effective at reducing risk factors for CVD, but do not prevent CVD as 
effectively as regular exercise.66 However, reduction of CVD risk factors, such as obesity, 
hypertension and diabetes, only accounts for 60% of the protective effect of exercise, leaving 40% 
unexplained (reviewed in Joyner and Green66). An important exercise-derived adaptation is 
improved endothelial function.67 Endothelial cells form a confluent monolayer covering the inner 
surface of blood vessels and act as the first point of contact between blood and tissues. The 
endothelium is important for coagulation, inflammation, vasodilation and angiogenesis.68 As with 
generalized exercise-derived adaptations, the mechanisms behind the improvement of endothelial 
function are not fully understood.67 Recently, improved endothelial function due to exercise has 
been linked, in part, to microvesicles (MV) released during exercise.54 
MVs are extracellular vesicles that range from 100 nm to one µm in diameter and are released 
from the plasma membrane in response to activation or apoptosis. They are present in all biological 
fluids, but are best characterized in blood. There are several populations of MVs in the circulatory 
system, derived from erythrocytes, leukocytes, endothelial cells, and platelets, with platelet MVs 
accounting for the majority.69 Within the circulatory system, MVs have many known functions, 
such as participating in hemostasis, angiogenesis, and cell-to-cell communication.70,71 They carry 
surface markers and cytokines derived from their cell of origin and modulate the biological 
function of cells they interact with.72 MVs also carry mRNA and microRNA, indicating the 
potential of impacting gene expression in target cells.10 While MVs have many important 
functions, they are also associated with several disease states, such as cancer, inflammation and 
atherosclerosis.73–75 The function of MVs varies depending on the cell of origin and stimulus of 
formation, resulting in a highly variable and versatile method of cellular communication.  
Several studies have found that exercise increases the concentration of circulating MVs, 
especially platelet MVs, by about two fold.55–58,76 Exercise causes several immediate physiological 
changes, including increased blood pressure, an increase in adenosine diphosphate (ADP), and 
release of cytokines such as IL-6, all of which have been shown to induce vesiculation.77,78 A 
recent study suggests that exercise-derived MVs improve endothelial function, but subsequent 
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studies have not been conducted.54 However, it has been proposed that exercise-derived MVs may 
be partially responsible for the protective effects of exercise, especially when considering 
endothelial cell health. How exercise-derived MVs differ from other MV populations is unknown 
and warrants further investigation. 
MVs may interact with target cells through external induction of signal transduction pathways 
by MV surface proteins or proteins released from MVs. However, endothelial cells have been 
shown to commonly take up MVs through receptor-mediated endocytosis.17,34,79,80 Leukocytes 
have also been shown to take up MVs, and accordingly MV concentrations quickly return to 
baseline due to this clearance after exercise.81,82 How MVs interact with target cells is as variable 
as their function. Generally, MV formation is accompanied by PS exposure on the outer leaflet of 
the plasma membrane. Exposed PS is involved in many uptake pathways of MVs, typically 
involving a receptor/ligand pair, the ligand of which binds PS, or direct interaction between PS 
and the target cell receptor.35,37,39,80 Most recently, the TAM receptor Axl, and its ligand Gas6, 
which binds PS, have been implicated in MV uptake.40 TAM receptors are best characterized in 
the phagocytosis of apoptotic cell particles by macrophages, and, because endothelial cells both 
secrete Gas6 and express surface Axl receptor, it is thought that this pathway could facilitate MV 
uptake by the endothelium.42 MVs also carry similar surface proteins to their cell of origin. In the 
case of platelet MVs, these surface proteins mainly consist of integrins and other adhesion 
proteins.83 These integrins allow platelets to adhere to proteins of the extracellular matrix, such as 
collagen.84 Platelet MVs may also be able to interact with endothelial cells through integrin 
proteins, although whether this mechanism leads to uptake is unknown. The mechanism by which 
exercise-derived MVs interact with target cells has not been investigated previously and is thus an 
important question to explore. 
3 OBJECTIVES 
The purpose of this study was to investigate the role of exercise-derived MVs in the protective 
effect of exercise on the endothelium. There were two overarching objectives for this project: 1) 
to determine the effect of exercise-derived MVs on endothelial cell function; and 2) to explore the 
mechanism of interaction between exercise-derived MVs and endothelial cells. Two functional 
assays were used to assess how MVs affected endothelial cells in culture, focusing on endothelial 
proliferation and wound healing. Blockade studies were set up in tandem with the functional assays 
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to study potential mechanisms of interaction. To investigate a general mechanism, MV surface 
proteins were degraded with trypsin. To investigate a more specific mechanism, the interaction 
between Axl and Gas6 was inhibited with an anti-Axl antibody. 
4 MATERIALS AND METHODS 
4.1 Ethics approval 
Ethical approval was obtained from the Thompson Rivers University Research Ethics Board 
before human exercise trials began (Appendix 9.1). All participants signed informed consent forms 
before taking part in the study and were financially compensated. 
4.2 Exercise trials 
Eleven healthy people between the ages of 18 and 39 participated in the exercise trial. Before 
the exercise trial, participants performed an incremental cycling test in which they exercised until 
exhaustion to determine their maximum output. After a five-minute warm-up with no added 
resistance, weight was added to the exercise bike in 0.2 kg increments to gradually increase the 
exercise intensity while the participants maintained 60 rpm. Throughout the test, heart rate was 
monitored by electrocardiography analyzed using Lab Chart software. Blood pressure and rate of 
perceived exertion (RPE) were taken at two minute intervals. The maximum power output was 
calculated as the product of the cycling speed (60 rpm) and the weight added to the exercise bike 
at the point of exhaustion. 
During the second visit, participants exercised on the exercise bike for one hour at 
approximately 60% of the max power output achieved during the first visit. A couple of 
participants were unable to maintain 60 rpm at 60% of the max power output and the intensity was 
adjusted accordingly. Heart rate was monitored throughout exercise and blood pressure and rate 
of perceived exertion were taken at 15 minute intervals. Blood lactate levels were measured with 
a Lactate Pro portable blood lactate analyzer every 15 minutes during exercise to ensure 
participants were exercising at a high intensity. After an hour of exercise, participants rested for 
an hour, while blood pressure and heart rate continued to be monitored. Lactate was measured 
again after an hour of recovery. 
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Figure 4. Exercise trial set up. Participants exercised for 60 minutes and then rested for 60 minutes. Blood was drawn and platelet 
count and hematocrit were measured at 0, 60 and 120 minutes. Plt = platelet; Hct = hematocrit. 
4.3 Blood processing and microvesicle isolation 
Blood was processed and MVs were isolated in accordance with the standardized protocol 
produced by the Society on Thrombosis and Haemostasis.25 Using an 18-gauge needle, 30 ml of 
venous blood were drawn by Dr. Mark Rakobowchuk, a certified phlebotomist, at three times 
points during the second visit: before (rest), after (exercise) and an hour after (recovery) exercise 
(Figure 4). Platelet count and hematocrit were determined within one hour of drawing blood. Four 
and a half ml aliquots of whole blood were transferred to tubes containing 0.5 ml of 0.109 M 
sodium citrate anticoagulant. The blood was centrifuged at 2500 x g for 15 minutes at room 
temperature to remove blood cells. The platelet poor plasma was transferred to 1.5 ml Eppendorf 
tubes and centrifuged again at 2500 x g for 15 minutes at room temperature to remove platelets. 
The MV-containing supernatant was transferred to new Eppendorf tubes and was flash frozen in 
liquid nitrogen and then stored at -80°C. 
4.4 Culture of human umbilical vein endothelial cells 
Human umbilical vein endothelial cells (HUVECs) pooled from multiple donors were used 
for the proliferation assay (Promocell C-12208). Immortalized HUVECS (Ea.hy 926 cell line, 
ATCC CRL-2922) were used for the scratch wound healing assay. HUVECs were cultured in 
M199 medium supplemented with 20% fetal bovine serum, 1% penicillin/streptomycin 
(AMRESCO K952-100ML), 0.5% 3 g/L endothelial cell growth supplement (Alfa Aesar BT-203), 
2% 1 M HEPES buffer, and 0.2% 2 mM pyruvate. Cells were grown in T75 flasks and incubated 
at 37°C with 5% CO2. Cells between passage three and five were grown to near-confluence and 
serum starved before use in assays. After removal from flasks with trypsin/EDTA, cell counts were 
performed using a hemocytometer and HUVECs were diluted to the proper concentrations for both 
assays. 
16 
 
4.5 Microvesicle treatment 
MV samples were thawed on the day of experiments or the night before. They were 
centrifuged at 17,000 x g for one hour to pellet MVs and the plasma supernatant was discarded, 
leaving 60 µL above the pellet. MVs were washed with PBS and centrifuged again at 17,000 x g 
for one hour. The supernatant was transferred to a clean Eppendorf tube and used for control 
treatments. For MV surface protein blockade, 60 µL MV samples from each time point were 
treated with 100 µL 0.25% trypsin/EDTA. The MVs were incubated for 30 minutes at 37°C before 
trypsin deactivation with growth medium containing 20% serum. The trypsin-treated MVs (tMV) 
were pelleted by centrifugation at 17,000 x g, the supernatant was discarded, leaving 60 µL above 
the pellet, and the pellet was resuspended. MVs were diluted to physiological concentrations for 
both assays. 
4.6 Proliferation assay 
All treatments were tested in triplicate with samples from six participants. The proliferation 
assay was conducted as described in Wilhelm et al. (2016).54 Ninety-six well plates were coated 
with 0.1% gelatin. Near-confluent HUVECs were remove from T75 culture flasks and resuspended 
at 40,000 cells/mL in serum free media. Fifty µL of cell suspension were added to each well along 
with another 50 µL serum free media and the appropriate MV treatment. For blockade of Axl/Gas6, 
the cell suspension was pre-incubated with anti-Axl antibody (R&D Systems AF154) or control 
IgG antibody (R&D Systems AB-108-C) for 30 minutes before addition to wells. The plates were 
incubated for four days at 37°C. 
The medium was removed and wells were washed with 100 µL PBS before addition of 100 
µL phenol-red free medium. Ten µL of 12 mM MTT reagent (thiazolyl blue tetrazolium bromide) 
(Sigma-Aldrich M5655) were added to each well and plates were incubated for three hours at 
37°C. After incubation, 80 µL of medium were removed from each well and 50 µL of dimethyl 
sulfoxide were added and plates were incubated for 10 minutes at 37°C. The absorbance of each 
well was measured at 540 nm and 620 nm using a Multiskan Ascent® plate reader (Thermo 
Electron 1507540). 
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4.7 Scratch wound-healing assay 
Treatments were tested in duplicate with samples from six participants, except for the tMV 
treatment which used samples from only five participants. Forty-eight well plates were coated with 
0.1% gelatin. Cells were removed from T75 culture flasks and resuspended in growth medium to 
50,000 cells/mL. Two hundred and fifty µL of cell suspension were added to each well and cells 
were cultured for six days until reaching confluence. 
HUVECs were serum starved over night before the day of the assay to ensure that cells 
would be in the same stage of the cell cycle at the beginning of the assay. Using a 200 µL pipet 
tip, a straight line was scratched down the middle of each well, removing part of the HUVEC 
monolayer. For Axl/Gas6 blockade, wells were treated with 1.25 ug anti-Axl antibody and 
incubated for 30 minutes at 37°C before wells were scratched. Wells were washed with PBS and 
imaged at baseline with a microscope camera using ToupView software before addition of MVs 
or supernatant. Wells were imaged again after two hours of incubation. Images were analyzed with 
ImageJ software to determine the area of the scratch wounds in pixels. 
4.8 Data analysis and statistics 
Values are reported as mean ± standard deviation. Missing data points from exercise trials 
were extrapolated or interpolated from mean values assuming a linear relationship between time 
points. Because the tMV data were missing from one participant in the scratch wound healing 
assay, a sample was added using the calculated mean from the five participants to achieve a sample 
size of six. 
Statistical analyses were performed with SPSS software. Exercise data were analyzed by one-
way repeated measures ANOVA (time) and assay data were analyzed using two-way repeated 
measures ANOVA with condition (MV, supernatant, anti-axl antibody, tMV) and time (rest, 
exercise, recovery) as factors. If a significant main effect or interaction was noted, a Sidak post 
hoc test was subsequently performed to identify specific differences between means. Significance 
for all analyses was set at P ≤ 0.05. 
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5 RESULTS 
5.1 Maximum power output 
This study involved eleven participants with an average age and body mass index (BMI) of 
24.8 ± 6.4 years and 23.9 ± 3.1 kg/m2, respectively. To determine maximum power output, 
participants exercised on an exercise bike until exhaustion, reaching an average maximum work 
rate of 245.3 ± 67.9 W. Participants achieved an average maximum heart rate of 189 ±8 beats per 
minute and an average maximum RPE of 8.6 ± 0.9 during the first visit (Table 1). 
Table 1. Participant characteristics from the initial visit used to determine optimal output for second visit. 
Participant Age BMI 
Max Output 
(W) 
Max Heart Rate 
(beats per minute) 
Max RPE 
/10 
01 20 25.53 120 - 9 
02 18 20.38 168 191 6.5 
04 25 25.38 228 195 10 
05 37 20.50 322 173 9 
06 20 24.37 252 183 8 
07 26 24.97 240 198 9 
08 20 30.85 300 195 9 
09 22 23.00 300 195 8 
10 23 25.76 288 183 9 
11 36 22.54 312 185 9 
12 26 20.10 168 190 8.5 
Average  
± SD 
24.8 
± 6.4 
23.94 
± 3.1 
245.3 
± 67.9 
189 
± 8 
8.6 
± 0.9 
 
5.2 Exercise trials 
As it was important to ensure that participants exercised at an adequate intensity to 
stimulate MV production during the exercise trial, heart rate, blood lactate levels, hematocrit and 
RPE were monitored throughout the hour of exercise (Table 2). Heart rate peaked at an average of 
170 ± 10 bpm (Figure 5D). Heart rate increased significantly within 15 minutes and remained 
elevated throughout exercise (P < 0.01), before returning to baseline 15 minutes after exercise. 
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Blood hematocrit increased by 2.6% with exercise but this increase was not found to be statistically 
significant after exercise (P = 0.06) or after recovery (P = 0.11) (Figure 5A). Lactate levels also 
increased with exercise (P < 0.01), peaking at 8.2 mmol/L after 30 minutes of exercise (Figure 
5C). Some participants were not able to maintain 60% of max output for the whole hour and the 
intensity decreased during the last 15 minutes of exercise. This is reflected in a slight decrease in 
lactate at 45 minutes, but lactate levels remained significantly increased compared to baseline. 
Mean platelet levels rose by 36.6% during exercise and were maintained throughout the hour of 
exercise and into recovery (P = 0.02) (Figure 5B). RPE reflected moderate activity after 15 minutes 
of exercise and increased to reflect vigorous activity by 45 minutes. The mean maximum RPE 
reported during the exercise trial was 0.6 points less than the mean maximum RPE reported during 
the first visit (Figure 5E).  
Table 2. Variables monitored throughout exercise trials. Values are mean ± SD. (-) indicates times at which variables were not 
measured. 
 Baseline Exercise Recovery 
Time 
(minutes) 
0 15 30 45 60 75 90 105 120 
Hematocrit 
(%) 
46.3 ±3.2 - - - 48.9 ±3.8 - - - 48.9 ±1.7 
Platelet (104 
per µL) 
5.7 ± 2.6 - - - 8.6 ±2.3 - - - 7.1 ±1.7 
Lactate 
(mmol/L) 
1.7 ±0.5 7.3 ±3.0 8.2 ±2.4 7.7 ±2.5 4.2 ±1.6 - - - 1.8 ±0.4 
Heart rate 
(BPM) 
84 ± 16 159 ±15 168 ±12 167 ±11 169 ±8 93 ±15 79 ±8 77 ±8 80 ±12 
RPE 0 5.4 ±1.1 6.9 ±0.7 7.5 ±1.3 8.0 ±0.8 - - - - 
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Figure 5. Measurements of several variables throughout 
the exercise trials. Increase in hematocrit was not 
statistically significant. Black circles indicate mean 
values and grey triangles indicate individual values 
with dotted lines to connect points from the same 
participant (A). Platelet levels were elevated after 
exercise and began to decrease during the hour of 
recovery (B). Blood lactate increased during exercise 
and decreased to baseline after an hour of recovery (C). 
Heart rate increased rapidly at the beginning of exercise 
and remained constant during an hour of exercise (D). 
Ratings of perceived exertion increased throughout 
exercise (E). Measures are mean ± SD. * indicates 
significant increase compared to baseline (statistical 
analysis was not run for RPE data). 
 
* 
* 
* 
* 
* 
* 
* * * 
A         B 
C         D 
E 
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5.3 Proliferation assay 
To determine the effect of exercise-derived MVs on the proliferation of endothelial cells, 
HUVECs were treated with MVs or supernatant from rest, exercise and recovery. The cells were 
then cultured in 96-well plates for four days before an MTT assay was used to determine the 
relative concentration of cells (Figure 6). Because the yellow MTT reagent is reduced by 
mitochondrial reductases to produce purple formazan, an increase in absorbance correlates to an 
increase in cell density. No significant differences were observed between the absorbance 
measured for MV treatment and supernatant controls (P = 0.62). Exercise MVs did not have a 
significant effect on proliferation (P = 0.12). 
Degradation of MV surface proteins and inhibition of the Axl/Gas6 interaction were used to 
investigate the mechanism of interaction between HUVECs and exercise MVs. The tMV treatment 
showed significantly more HUVEC proliferation than the MV treatment (P = 0.02) and supernatant 
treatment (P = 0.02) at all time points. Blockade with anti-Axl antibody resulted in increased 
proliferation of HUVECs over supernatant treatment (P < 0.01) but not over MV treatment (P = 
0.15). 
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Figure 6. Average absorbance of different treatments measured at 540 nm for the proliferation assay. Averages were calculated 
from six samples run in triplicate. Measures are mean ± SD. MV = microvesicle; SN = supernatant; AB = anti-Axl antibody; 
tMV = trypsin-treated MVs. ᵻ shows significant difference from MV treatment; * shows significant difference from supernatant 
treatment within time point.  
5.4 Scratch wound healing assay 
To determine the effect of MVs from different time points on the migration and wound-
healing abilities of endothelial cells, a straight line was scratched in confluent monolayers of 
HUVECs. HUVECs were then treated with MVs or supernatant and wound closure was monitored 
over two hours (Figure 7). As with the proliferation assay, blockades were also set up to investigate 
the mechanism of interaction between endothelial cells and MVs. No significant differences in 
wound closure were observed between treatments with rest, exercise and recovery MVs (P = 0.48). 
However, there was a significant condition by time interaction where the resting MV treatment 
resulted in decreased migration of cells into the scratch wound than the resting tMVs (P = 0.04). 
Exercise MVs induced more wound closure when HUVECs were pretreated with anti-Axl 
antibody, compared to cells not exposed to the blockade (P < 0.01). Unexpectedly, treatment with 
supernatant from the recovery time point resulted in improved wound closure over recovery MVs 
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(P = 0.002). Treating HUVECs with tMVs from rest resulted in more wound closure than tMVs 
from recovery (P = 0.02). 
 
Figure 7. The change in area of HUVEC scratch wounds over two hours. Measures are mean ± SD. MV = microvesicle; SN = 
supernatant; AB = anti-Axl antibody; tMV = trypsin-treated MVs. Matching symbols indicate significant differences between 
treatments.  
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6 DISCUSSION 
6.1 Exercise intensity 
The purpose of the exercise trials was to have participants exercise at a high intensity to 
induce the production of MVs. Therefore, maximum work rates were determined during the 
participants’ initial visit. During the exercise trial, participants exercised at 60% of their maximum 
work rate to ensure a high level of physical exertion that would be sustainable for the full hour of 
exercise. Several parameters indicative of exercise intensity were monitored throughout exercise 
to provide support for the attainment of a vigorous exercise stimulus previously highlighted as an 
important variable leading to MV appearance with exercise. 
Heart rate may be used as an appropriate measure of exercise intensity, with values above 
80% of maximal heart rate indicative of vigorous activity. The maximum average heart rate 
reached 170 ± 10 bpm during the hour of exercise, compared to the average maximum heart rate 
of 189 ± 8 bpm during maximum output testing, indicating that participants did not reach 
maximum output during the hour of exercise. However, 170 bpm does indicate intense physical 
exertion at ~90% of maximal, which would be considered within the heavy exercise domain and 
likely to induce MV formation.54 
During high intensity exercise, the metabolite lactate is released from skeletal muscle cells. 
The average lactate level of 1.6 ± 0.5 mmol/L recorded at baseline is typical for individuals at 
rest.85 The maximum average lactate level of 8.2 ± 2.4 mmol/L indicates that a steady state of high 
intensity exercise was achieved throughout the last 30 minutes, again suggesting participants 
exercised at a high enough intensity to produce MVs.85 Lactate levels peaked at 30 minutes and 
then declined slightly during the second half of the exercise trial because some participants were 
exercising at an intensity too high to maintain for the entire hour. Although it was necessary to 
decrease the intensity of exercise for some participants, based on blood lactate data it can be 
concluded that participants were exercising at a high intensity throughout the hour. 
During exercise, the red blood cell concentration increases due to fluid loss and lowering of 
plasma levels as plasma shifts to the extracellular compartment. This is an important adaptation to 
exercise, as red blood cells contribute to the buffering of blood pH by binding protons and CO2, 
and supply tissues with oxygen.86 Thus, measuring the percentage of blood composed of 
erythrocytes gives insight into the intensity of exercise. The observed increase in hematocrit during 
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the hour of exercise and after recovery was not significant, indicating that the participants were 
not exercising at a high enough intensity to induce fluid loss.  
The reported RPE indicated that participants felt a relatively high strain during the hour of 
exercise. However, RPE is subjective and thus is not a measure of true exertion. Nevertheless, 
RPE does reveal information about the psychological state of participants, allowing researchers to 
adjust exercise parameters so that participants were able to complete a full hour of exercise. 
Since exercise increases platelet concentrations and activates platelets through shear stress, 
it is expected that higher levels of platelets associated with exercise will result in an increase in 
MVs.87 Platelet concentrations increased by 36.6% after the hour of exercise, suggesting that MV 
concentrations would have also increased. These changes in blood platelet concentrations mirrored 
those of Wang et al., who found that intense exercise increased platelet levels by 24.7%.88 
6.2 Effect of exercise MVs on endothelial cell function 
To investigate whether exercise-derived MVs improved endothelial function, two assays 
were used to assess the proliferative and wound closing abilities of HUVECs treated with MVs or 
supernatant collected from participants during rest, exercise and recovery. The results of this study 
are inconclusive when considering how exercise MVs affect endothelial function. There were no 
observed differences in HUVEC proliferation between treatments with MVs from rest, exercise 
and recovery, suggesting that either exercise does not increase MV concentrations or that the MVs 
produced by exercise have no inherent effect on the proliferative ability of endothelial cells. 
Similarly, MVs from exercise did not improve wound closure compared to MVs from rest or 
recovery. These results are in contention with a recent study that showed increased proliferation, 
migration and wound healing of endothelial cells treated with exercise MVs, as well as several 
studies linking PMVs to improved endothelial function and neovascularization.50–52,54 Although it 
appears that the participants achieved a high intensity of exercise, it is possible that the exercise 
was insufficient for MV production. However, moderate exercise has previously been shown to 
induce the release of platelet MVs.56 
Unexpectedly, at the recovery time point, the supernatant control improved wound closure 
over the MV treatment. The control treatment was the resulting supernatant after washing MV 
samples with PBS and should have contained relatively little protein or other constituents found 
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in plasma. As such, it was hypothesized that the supernatant would have little effect on endothelial 
cells. It is possible that the MV treatment had a negative effect on the endothelial cells due to the 
presence of pro-coagulant PMVs. During blood draw, an 18-gauge needle was used to avoid shear 
stress-induced platelet activation, but it appears that the sodium citrate anticoagulant did not work 
as unwashed MV samples and the plasma supernatant induced coagulation when added to the 
functional assays. This finding was not consistent between assays, however, with no difference in 
endothelial proliferation between MV and supernatant treatments, indicating that MVs negatively 
affect wound closure, but not proliferation. Although proliferation is necessary for wound closure, 
other processes, such as migration, are involved and the MV treatment may have been detrimental 
to these processes, resulting in reduced wound closure. 
6.3 Mechanism of interaction between MVs and endothelial cells 
To investigate the mechanism of interaction between endothelial cells and exercise-derived 
MVs, potential uptake mechanisms were inhibited. Previous studies have suggested that MV 
surface proteins, such as glycoproteins and integrins, may be involved in the receptor-mediated 
endocytosis of MVs by endothelial cells and it was hypothesized that these proteins might mediate 
the interaction between exercise-derived MVs and endothelial cells.36 To inhibit interactions 
involving MV surface proteins, these proteins were degraded with trypsin. It was expected that if 
MV surface proteins mediate the interaction, degradation of these proteins would inhibit the 
interaction and dampen the effect of exercise-derived MVs on endothelial function. However, 
tMVs had the opposite effect, increasing proliferation regardless of whether the treated MVs were 
from rest, exercise or recovery. This effect was also seen in the scratch wound healing assay, as 
tMVs from rest increased wound closure over rest MVs. Previous studies have indicated a role of 
MV glycoproteins in MV interaction with endothelial cells, and so degradation of these proteins 
should reduce the effect of MVs.34 However, MV phospholipids, specifically PS, have been 
implicated in mediating MV uptake and thus the degradation of surface proteins may make these 
phospholipids more accessible.17 As trypsin degradation may destabilize MV membranes, it is 
possible that MVs lysed, rather than remaining intact. This would result in MV contents being 
released into the medium, rather than MVs being taken up by endothelial cells. Platelet MVs 
contain high concentrations of platelet-derived endothelial cell growth factor (PDEGF) and VEGF, 
which induces endothelial proliferation and migration, as well as a host of proteins involved in 
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signal transduction and cell communication.83 Although the contents of exercise-derived MVs 
have not yet been characterized, it is possible that these proteins were present, and their release 
into the medium has a greater effect than MV uptake. This is probable when considering the effect 
of PDEGF and VEGF, as these growth factors bind to extracellular membrane-bound receptors, 
which induce a signal cascade that results in endothelial proliferation and migration. As such, 
internalization of MVs would fail to activate these pathways, especially if MVs are taken into 
lysosomes for disposal. 
Such dramatic effects of tMVs on proliferation may have been due to microbial 
contamination of the assay. Although penicillin and streptomycin were used to control potential 
bacterial contamination, no antifungal agents were used. This lack of antifungal agent, combined 
with several instances of contamination throughout the project, indicates that the increased 
proliferation may actually be caused by microbes growing in the wells rather than HUVECs. It is 
unlikely that the trypsin was the source of contamination, however, as the stock was used 
throughout the project for removal of cells from flasks. Unfortunately, the plates were not 
examined by microscopy after incubation with the MTT reagent, nor were contaminants isolated, 
so fungal contamination was not confirmed. 
A recent study has implicated Axl and Gas6 in the receptor-mediated endocytosis of PMVs 
by endothelial cells and it was thought that this pathway may be involved in the uptake of exercise-
derived MVs.40 An antibody specific to the endothelial surface receptor, Axl, was used to block 
the interaction between MVs and endothelial cells through Axl and Gas6 bound to MV PS. It was 
expected that, if the Axl/Gas6 pathway is active in the interaction between exercise-derived MVs 
and endothelial cells, blocking the Axl/Gas6 interaction would decrease any beneficial effects seen 
with exercise-derived MVs. As with the trypsin treatment, antibody treatment increased 
endothelial cell function under several conditions. Axl blockade resulted in increased proliferation 
over supernatant treatments, although no difference was found between antibody and MV 
treatments. Antibody treatment of HUVECs also increased wound closure when cells were treated 
with exercise MVs. It was hypothesized that blockade of the Axl/Gas6 interaction would decrease 
the effect of MVs on endothelial cells. However, inhibition of the Axl/Gas6 pathway may have 
prevented uptake and caused MVs to remain in the media where lysis could occur, producing 
results similar to that of the tMVs. It can be assumed that the antibody used in this experiment 
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inhibits the interaction between Gas6 and Axl as this antibody was used in a previous study that 
showed effective blockade.40 It is possible that the Axl/Gas6 pathway is not involved in the uptake 
of exercise MVs. Connor et al. (2010) showed that only a small population (~10%) of circulating 
MVs in unstimulated platelet-poor plasma bind annexin V, which indicates PS exposure.24 Further, 
when stimulated by ADP or TRAP, which are both agonists relevant in an exercise model, less 
than 25% of PMVs bind annexin V.24 However, the percentage of annexin V binding varies greatly 
depending on buffer as well as stimulus. Nevertheless, this finding calls into question how 
prevalent PS+ MVs are and what mechanisms are involved in the uptake of PS- MVs. 
6.4 Limitations 
A major flaw in the execution of this study was the anticoagulant used when collecting blood 
samples during the exercise trials. As MV and platelet poor plasma samples induced coagulation 
upon addition to assays, it can be assumed that the sodium citrate treatment of blood samples failed 
to prevent activation of platelets and coagulation factors. Sodium citrate is a chelating agent that 
interacts with calcium ions, preventing activation of platelets. It is probable that the sodium citrate 
was prepared using PBS rather than water, which would effectively deactivate the sodium citrate 
by overwhelming the chelating ability of the anticoagulant. Because calcium is involved in platelet 
activation, the deactivated anticoagulant would result in the activated platelets shedding MVs, 
inflating the concentration of MVs in the samples. Further, these PMVs would presumably have 
different properties than exercise-derived MVs and may account for the reduction in proliferation 
and wound healing seen in the functional assays. An alternate explanation for the sample 
coagulation is that the initial blood samples were not centrifuged at a high enough speed to 
completely remove platelets from the samples. Although a standardized protocol from the Society 
on Thrombosis and Haemostasis was used, reported centrifugation speeds for similar experiments 
are much higher, ranging from 3,200 x g to 13,000 x g.10,34 Because of the procoagulant nature of 
the samples, the supernatant control had to be adjusted. The appropriate control would have been 
the plasma resulting from the initial centrifugation of MV samples, as this control would indicate 
whether other plasma constituents, such as lipids, proteins or exosomes, are responsible for any 
effects seen through the assays. However, as addition of plasma caused coagulation, it was not 
possible to use this treatment, and the PBS supernatant after washing MV samples was used 
instead. 
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Due to the coagulation issues, a third blockade study using annexin V, which binds PS and 
thus blocks PS interactions with other receptors, was not possible. Although washing the MV 
samples with PBS was sufficient to prevent coagulation, MV samples with annexin V caused 
coagulation because annexin V binding of PS is calcium dependent and the binding buffer 
contained calcium, which induces coagulation by activation of platelets and production of 
thrombin from prothrombin. This adds evidence to the theory that not all platelets and platelet 
fragments were removed with the relatively low speed centrifugation. 
A major limitation to this study was the lack of laminar flow conditions to simulate the flow 
of blood within vessels, which is important for maintaining proper health and function of 
endothelial cells. Without flow conditions, it is unclear whether the results from this study, and 
others conducted under static conditions, can be translated to in vivo conditions. Without flow 
conditions, MVs can settle onto the endothelial cell monolayer and have a prolonged period to 
interact with the cells. However, under flow conditions, it is unclear whether MVs would be in 
contact with the endothelium long enough to allow uptake. Although implementation of a laminar 
flow chamber was considered for this project, there was not enough time to get one built. As well, 
while using a flow chamber would have allowed for conditions more similar to physiological 
conditions, few functional MV experiments have been conducted using flow chambers. As such, 
using a flow chamber would have made the results of the current study difficult to compare to 
relevant literature. 
Another important element missing from this study is the quantitation of MVs. Without 
analysis of the samples, it cannot be concluded whether MV concentrations increased with 
exercise, or if MVs were present at all. It was planned that samples would be sent to Brunel 
University or the University of British Columbia Okanagan to be analyzed by flow cytometry. 
However, due to timing and logistical problems this never happened and samples were not sent 
elsewhere for analysis. Without a flow cytometer at Thompson Rivers University, quantification 
of MVs is difficult. However, MV concentrations could potentially be measured by electron 
microscopy, although this measure is fairly inaccurate and would only produce a rough estimate. 
Enzyme-linked immunosorbent assay could also be used to quantify MVs, but this would require 
an assumption of which proteins are present on the membrane of MVs. As exercise-derived MVs 
have yet to be characterized, assuming surface markers could result in an underestimation of MV 
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concentrations. However, both measures can be done with the resources available at Thompson 
Rivers University and would add value to future experiments. 
7 CONCLUSIONS AND FUTURE WORK 
The results of this study call into question the beneficial nature of MVs. While MVs have 
been associated with adaptive effects on the endothelium, they have also been implicated in disease 
states and coagulation. However, meaningful conclusions cannot be drawn from this research as 
results were not consistent between assays and contamination may have been responsible for some 
of the significant results. It is reasonable to conclude that the experiments should be repeated to 
determine whether the assays were working as expected. New samples should be obtained before 
repetition of assays, and anticoagulants should be tested before use. Quantification of MV samples 
would also add value as it is important to both verify the presence of MVs and to indicate whether 
effects are the result of increased MV concentrations or whether exercise MVs are inherently 
different from resting MVs. An important next step to understanding the function of exercise-
derived MVs is characterization of the protein and mRNA content. This would supplement 
blockade assays by giving direct evidence of potential targets, rather than choosing targets based 
on studies that involve PMVs derived from other modes of activation. 
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